IP Library Granted Patent US 8,377,876
Granted Patent B2
US 8,377,876 · App. 12/226,358 · Granted Feb 19, 2013

Pediatric amino acid solution for parenteral nutrition

Inventors: Ortrud Brand (Ostfildern, DE); Thorsten Erbe (Butzbach, DE); Georg Achleitner (Graz, AT); Norbert Feichtinger (Graz, AT)
Assignee: Fresenius Kabi Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,377,876
App. No.
12/226,358
Granted
Feb 19, 2013
Kind
B2
Abstract

The present invention relates to an amino acid solution for the parenteral nutrition of pediatric patients. The amino acid solution provides for an increased concentration of glutamine, tyrosine, cysteine and taurine, while the concentrations of phenylalanine and methionine is small. Glutamine and tyrosine are provided in the form of oligopeptides.

Claims (25)

1. A solution for parenteral nutrition of pediatric patients, characterized in that the solution comprises 1-4 g tyrosine per 100 g of amino acids, 3-5 g phenylalanine per 100 g of amino acids, 0.3-1.5 g cysteine per 100 g of amino acids, 1-3 g methionine per 100 g of amino acids, 9-30 g glutamine per 100 g of amino acids and 0.3-2 g taurine per 100 g of amino acids.

2. The solution according to claim 1 , further comprising glutamine in the form of oligopeptides.

3. The solution according to claim 1 , further comprising tyrosine in the form of oligopeptides having a chain length of at most 5 amino acid units.

4. The solution according to claim 2 , wherein the oligopeptides are dipeptides or tripeptides.

5. The solution according to claim 2 , wherein the glutamine in the form of oligopeptides is present in the form of alanyl glutamine, glycyl glutamine or mixtures thereof.

6. The solution according to claim 3 , wherein the tyrosine in the form of oligopeptides is present in the form of glycyl tyrosine, alanyl tyrosine or mixtures thereof.

7. The solution according to claim 1 , wherein the solution contains at most 3 g/l glutamic acid.

8. The solution according to claim 1 , wherein the solution comprises 3-30% w/w protein building blocks.

9. The solution according to claim 1 , wherein the ratio of tyrosine to phenylalanine is from 1:1 to 1:3.

10. The solution according to claim 1 , wherein the combined amount of the amino acids cysteine, taurine and methionine is 2-5% of all amino acids.

11. The solution according to claim 1 , wherein the solution contains less than 1% proteins or peptides having a chain length >5 amino acid units.

12. A medical composition for complete parenteral nutrition, comprising:

a) the solution according to claim 1 ,

b) carbohydrates, and

c) fats,

wherein said solution, said carbohydrates and said fats each provide enerqy upon consumption,

wherein the solution provides 10-20% of the total energy, the carbohydrates provide 30-60% of the total energy, and the fats provide 30-50% of the total energy provided by the composition, and

wherein the proportions of energy provided by the solution, the carbohydrates and the fats add up to 100%.

13. The medical composition according to claim 12 , additionally comprising electrolytes, vitamins and trace elements.

14. A method of preparing a sterile solution, comprising:

preparing the solution according to claim 1 , wherein the 9-30 g glutamine per 100 g of amino acids in the form of oligopeptides, and

thermally sterilizing the solution at a temperature of ≧124° C.

15. A method of providing parenteral nutrition to a pediatric patient suffering from at least one selected from malformation of the bowel, inflammation of the bowel, a renal disorder and a hepatic disorder, the method comprising:

administering to a patient in need thereof the solution according to claim 1 .

16. The medical composition according to claim 12 , wherein the medical composition is a parenteral infusion solution for administration to pediatric patients comprising a daily dose of 90-180 kcal/kg body weight of the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 21, 2008
From: BRAND, ORTRUD; ERBE, THORSTEN; ACHLEITNER, GEORG; FEICHTINGER, NORBERT
To: FRESENIUS KABI DEUTSCHLAND GMBH
Reel/Frame 021909/0510 →
Priority Claims (1)
DE 10 2006 018 293 · Apr 20, 2006 · national
Continuity (1)
Related Publication 20090203626A1 · Aug 13, 2009